Compare DEI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | NVCR |
|---|---|---|
| Founded | 1971 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2006 | 2015 |
| Metric | DEI | NVCR |
|---|---|---|
| Price | $12.38 | $18.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $12.94 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | $655,353,000.00 |
| Revenue This Year | $1.70 | $7.72 |
| Revenue Next Year | $2.35 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.77 | ★ 8.28 |
| 52 Week Low | $9.04 | $9.82 |
| 52 Week High | $16.94 | $20.55 |
| Indicator | DEI | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 59.61 |
| Support Level | $11.15 | $12.85 |
| Resistance Level | $12.70 | $18.48 |
| Average True Range (ATR) | 0.41 | 1.11 |
| MACD | -0.02 | 0.24 |
| Stochastic Oscillator | 52.24 | 51.76 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.